Literature DB >> 20014416

A comprehensive approach to the treatment of uterine leiomyomata.

Karen Stein1, Charles Ascher-Walsh.   

Abstract

Leiomyomas (fibroids) are the most common tumors in women, with a prevalence between 30% and 50%. They affect women primarily during their reproductive years, spontaneously regressing after menopause in most women. They may cause significant symptoms of pain, dysmenorrhea, abnormal uterine bleeding, and infertility. Because leiomyomas are so common, treatment should be reserved for those patients with symptoms. Treatment options have recently expanded beyond hysterectomy. Medical therapies, including gonadotropin-releasing hormone agonists and progesterone modulators, have become more widely used. Less invasive options such as uterine fibroid embolization, magnetic resonance imaging-guided focused ultrasound, and radiofrequency ablation are being used to avoid more invasive surgery. Because of limited and negative information regarding these alternatives to surgery, they are not recommended for women desiring future fertility. If surgery is desired or required, often less invasive approaches via hysteroscopy for intracavitary lesions or robot-assisted laparoscopy for patients with a small number of myomas have become preferred options. Treatment should be tailored to the patient. Copyright 2009 Mount Sinai School of Medicine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20014416     DOI: 10.1002/msj.20145

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  9 in total

1.  1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model.

Authors:  Sunil K Halder; Chakradhari Sharan; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2012-04-19       Impact factor: 4.285

Review 2.  Uterine fibroids and current clinical challenges.

Authors:  Salama S Salama; Gökhan S Kılıç
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-03-01

3.  Self-reported family history of leiomyoma: not a reliable marker of high risk.

Authors:  Tina Marie Saldana; Malana Moshesh; Donna Day Baird
Journal:  Ann Epidemiol       Date:  2013-05       Impact factor: 3.797

4.  Tranexamic acid for the management of uterine fibroid tumors: A systematic review of the current evidence.

Authors:  Panagiotis Peitsidis; Anna Koukoulomati
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

5.  A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years.

Authors:  D D Baird; T M Saldana; D L Shore; M C Hill; J M Schectman
Journal:  Hum Reprod       Date:  2015-09-25       Impact factor: 6.918

6.  Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease.

Authors:  Jung-Yun Lee; Hyun Soo Kim; Eun Ji Nam; Sang Wun Kim; Sunghoon Kim; Young Tae Kim
Journal:  BMC Cancer       Date:  2016-08-23       Impact factor: 4.430

Review 7.  Role of Transforming Growth Factor β in Uterine Fibroid Biology.

Authors:  Michał Ciebiera; Marta Włodarczyk; Małgorzata Wrzosek; Błażej Męczekalski; Grażyna Nowicka; Krzysztof Łukaszuk; Magdalena Ciebiera; Aneta Słabuszewska-Jóźwiak; Grzegorz Jakiel
Journal:  Int J Mol Sci       Date:  2017-11-17       Impact factor: 5.923

8.  The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas.

Authors:  Qi Shen; Li Shu; Hui Luo; Xiaoli Hu; Xueqiong Zhu
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

9.  Utility of magnetic resonance imaging for differentiating malignant mesenchymal tumors of the uterus from T2-weighted hyperintense leiomyomas.

Authors:  Koichiro Matsuura; Kaiji Inoue; Eri Hoshino; Masanori Yasuda; Kosei Hasegawa; Yoshitaka Okada; Yasutaka Baba; Eito Kozawa
Journal:  Jpn J Radiol       Date:  2021-11-09       Impact factor: 2.374

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.